UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or ...

Amgen Inc. (NASDAQ:AMGN) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 October 24, 2023 8:00 AM ET Company Participants David Reese – Executive Vice President-Research and Development Taofeek Owonikoko – Division Chief-Division of Hematology-Oncology, UPMC Hillman Cancer Ctr. Tarlatamab Jean-Charles Soria – Senior Vice President-Research and Development Kevin Kelly – Chair, Department of Medical Oncology, Sidney Kimmel Medical College Conference Call Participants Salvee ...

Hematology/Oncology Update ESMO 2023 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_f40de14a20e804d3a6af5c7e984f91c3.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4f034bd9fec7da888ff907c6390a7800.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_a86cfbdc1df4a04c795f2267227eb86a.html ...

Q2 ’23 Earnings Call Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsthatarebasedonthecurrentexpectationsandbeliefsofAmgen. Allstatements,otherthanstatementsofhistoricalfact,arestatementsthatcouldbedeemedforward-looking statements,includinganystatementsontheoutcome,benefitsandsynergiesofcollaborations,orpotentialcollaborations,withanyothercompany(includingBeiGene,Ltd.orKyowa-KirinCo.,Ltd.),theperformanceofOtezla®(apremilast) (includinganticipatedOtezlasalesgrowthandthetimingofnon-GAAP ...

Amgen Inc. (NASDAQ:AMGN) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Arvind Sood – Vice President of Investor Relations Bob Bradway – Chairman and Chief Executive Officer Murdo Gordon – Executive Vice President, Global Commercial Operations Dave Reese – Executive Vice President, Research and Development Peter Griffith – Chief Financial Officer Conference Call Participants Mohit Bansal – Wells Fargo Michael Yee – Jefferies Salveen Richter – Goldman Sachs Jay Olson – Oppenh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or orga ...

Summary of Amgen Inc. Conference Call Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Goldman Sachs 44th Annual Global Healthcare Conference - **Date**: June 14, 2023 - **Participants**: Robert Bradway (Chairman and CEO), Salveen Richter (Goldman Sachs) Key Points Industry Context - The healthcare and biopharma sectors are experiencing significant regulatory scrutiny, particularly regarding mergers and acquisitions, as evidenced by the FTC's move to block Amgen's acquisition of Horizon Therapeutics [2][3][4]. Acquisition of Horizon Therapeutics - Amgen remains optimistic about the acquisition, asserting that there are no anti-competitive issues that should prevent the merger [3][4]. - The company is preparing for a hearing in autumn 2023 to present its case against the FTC's concerns [3][6]. - Amgen expects the deal to close by mid-December 2023, pending the outcome of the hearing [5][6]. TEPEZZA Sales Performance - TEPEZZA sales have been weaker than anticipated, but Amgen remains confident in the product's potential and is actively working to expand its market presence [9][10][12]. - Data shows a significant benefit of TEPEZZA in chronic disease patients, with a 62% efficacy rate compared to 7% for placebo [12]. Biosimilars Business - Amgen has successfully launched AMJEVITA, a biosimilar, and is positioned as a leader in the biosimilars market [14][15]. - The company has launched six biosimilars and plans to launch five more, expecting to double its biosimilars business compared to 2021 levels [15][17]. - Amgen emphasizes the importance of being among the first to launch biosimilars to capture market share [14][16]. Hematology/Oncology Portfolio - The hem/onc business is performing well, driven by strong data supporting the efficacy of its products, particularly BLINCYTO [25][26]. - BLINCYTO is noted for its potential to improve outcomes in leukemia patients, and the company is excited about its subcutaneous formulation [26][27]. - Other products in the portfolio, such as Vectibix and KYPROLIS, are also showing strong performance [27]. Long-term Guidance and Growth - Amgen has reiterated its long-term guidance, citing strong growth in in-line products and international markets [30][32]. - The company reported a 20% volume growth in Europe and 35-36% in the Japan-Asia region [32]. - Amgen is optimistic about its pipeline, including potential breakthroughs in cancer therapies and treatments for cardiovascular diseases [33][54]. Challenges and Regulatory Environment - The Inflation Reduction Act is viewed negatively by Amgen, as it may hinder innovation and affect patient access to new therapies [46][47]. - Price pressure in the pharmaceutical industry is expected to continue, necessitating operational efficiency [57][58]. Innovation and AI Integration - Amgen is leveraging AI and machine learning to enhance its research capabilities and improve drug development processes [60][62]. - The company is focused on using human genetic data to inform its drug development strategies [61]. Capital Allocation Strategy - Amgen's capital allocation strategy includes investing in innovation, returning capital to shareholders, and paying down debt incurred from the Horizon acquisition [64]. Additional Insights - Amgen is committed to addressing unmet medical needs, particularly in oncology and rare diseases, and is excited about the potential of its innovative therapies [52][54]. - The company is adapting to regulatory changes and market dynamics while maintaining a focus on long-term growth and patient care [48][49].